Literature DB >> 1116154

The pharmacokinetics of 4-acetyl tritium vinblastine in two patients.

R J Owellen, C A Hartke.   

Abstract

Vinblastine, labeled with tritium in the 4-acetyl group, was given to two patients with malignant disease, and the pharmacokinetic behavior of the drug was determined. Clearance of radioactivity from the blood was biphasic, with t1/2 values for a first rapid phase of 4.25 and 4.78 min, and for a slower phase of 185 and 195 min. The volume of the central compartment was calculated as 29.7 and 39.4 liters, while the total fictive volume of distribution was 86.4 and 111.4 liters. Binding to blood components occurred in the order: plasma greater than platelets greater than red blood cells greater than white blood cells. Excretion of radiolabel occurred via the stool and the urine so that, after 72 hr, 25 and 41% of the total dose had appeared in the former and 19 a nd 23% had appeared in the latter. Appreciable amounts of unchanged drug appeared in the urine, while very little appeared in the stool, suggesting hepatic metabolism, consistent with prior animal studies.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1116154

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 3.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

4.  A sensitive radioimmunoassay for vincristine and vinblastine.

Authors:  V S Sethi; S S Burton; D V Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.

Authors:  V S Sethi; P Surratt; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods.

Authors:  P Boré; R Rahmani; J van Cantfort; C Focan; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.

Authors:  H W Van den Berg; Z R Desai; R Wilson; G Kennedy; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 8.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.